SCHEMBL4769037

SCHEMBL4769037

c1ccc(-c2nc(NCCCn3cncn3)cc(-c3cccnc3)n2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 2/20 0.43
GSK3B P49841 2/20 0.43
CSNK2A2 P19784 1/20 0.43
FGFR2 P21802 1/20 0.43
KDR P35968 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CSNK1D P48730 1/20 0.43
CSNK1E P49674 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
CSNK1G2 P78368 1/20 0.43
CSNK1G1 Q9HCP0 1/20 0.43
ROS1 P08922 3/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2A6 P11509 1/20 0.41
TLR9 Q9NR96 1/20 0.41
HDAC1 Q13547 6/20 0.41
SLC2A1 P11166 1/20 0.40
HDAC6 Q9UBN7 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3630638 0.83 SMN1; SMN2 (0.55) GSK3AGSK3BSMN1; SMN2NPC1TP53
SCHEMBL4769045 0.78 HDAC1 (0.48) CYP3A4CYP2C9CYP2A6HDAC1SLC2A1
SCHEMBL4777383 0.77 METAP1 (0.47) KDRROS1CYP3A4CYP2C9HDAC1
SCHEMBL2240945 0.77 GBA1 (0.54) CYP3A4CYP2C9CYP2A6SLC2A1SMN1; SMN2
SCHEMBL2238098 0.77 PTGDR (0.53) CYP3A4CYP2C9CYP2A6SLC2A1SMN1; SMN2
SCHEMBL2242543 0.77 CYP2C9 (0.42) ROS1CYP3A4CYP2C9CYP2A6HDAC1
SCHEMBL4774987 0.77 ADORA2A (0.46) GSK3BROS1CYP3A4CYP2C9CYP2A6
SCHEMBL4765978 0.77 HDAC1 (0.44) ROS1CYP3A4CYP2C9CYP2A6HDAC1
SCHEMBL3627886 0.76 SMN1; SMN2 (0.60) GSK3AGSK3BROS1CYP3A4CYP2C9
SCHEMBL2240174 0.76 CYP3A4 (0.42) ROS1CYP3A4CYP2C9CYP2A6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed